April 17, 2026 · Form 4 insider transaction
Collins Helen Louise bought 5,000 shares of Enliven Therapeutics, Inc. at $2.48 per share, a transaction worth $12.4K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.; Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.